Certara

67 articles about Certara

• Certara Announces 300th Regulatory Submission Milestone Using its Technology-enabled Services and Software

  9/19/2023

  Certara, Inc., a global leader in biosimulation, announced it has successfully supported 300 completed submissions to regulatory agencies worldwide.

• Certara to Participate in Upcoming September 2023 Investor Conferences

  8/29/2023

  Certara, Inc., a global leader in biosimulation, announced that Company management will participate in the following investor conferences.

• Certara Reports Second Quarter 2023 Financial Results

  8/9/2023

  Certara, Inc., a global leader in biosimulation, reported its financial results for the second quarter of fiscal year 2023.

• Certara to Report Second Quarter 2023 Financial Results on August 9th, 2023

  7/13/2023

  Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it will release financial results for the second quarter of 2023 after the market close on Wednesday, August 9th, 2023.

• Certara to Participate in the 2023 Jefferies Global Healthcare Conference

  6/2/2023

  Certara, Inc., a global leader in biosimulation, announced that Company management will participate in the Jefferies Global Healthcare Conference.

• Certara Reports First Quarter 2023 Financial Results

  5/8/2023

  Certara, Inc., a global leader in biosimulation, reported its financial results for the first quarter of fiscal year 2023.

• Certara Customers Received 90 Percent of US FDA Novel Drug Approvals for 9th Consecutive Year

  4/27/2023

  Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that 90 percent of new drug approvals by the U.S. Food and Drug Administration’s (FDA) Center for Drug Evaluation and Review (CDER) were received by Certara’s customers in 2022.

• Certara to Report First Quarter 2023 Financial Results on May 8th, 2023 and Participate in the BofA Securities 2023 Healthcare Conference

  4/10/2023

  Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it will release financial results for the first quarter of 2023 after the market close on Monday, May 8th, 2023.

• A.I. Coming to Certara’s D360 Scientific Informatics Software

  3/9/2023

  Certara, Inc., a global leader in biosimulation, is adding deep learning capabilities to D360, a leading scientific informatics software platform.

• Certara announces the release of Simcyp™ PBPK Simulator Version 22, expanding ability to simulate untested scenarios for new patient and therapeutic types

  3/7/2023

  Certara, Inc., a global leader in biosimulation, announced the release of Simcyp Simulator Version 22, which includes new capabilities and updated features to the Company’s population-based modeling and simulation platform.

• Certara Reports Fourth Quarter and Full Year 2022 Financial Results

  3/1/2023

  Certara, Inc., a global leader in biosimulation, reported its financial results for the fourth quarter and full year of 2022 and issued guidance for 2023.

• Certara Announces Transition Plan for Chief Financial Officer

  3/1/2023

  Certara, Inc., announced that John Gallagher will succeed Andrew Schemick as Chief Financial Officer, effective April 1, 2023.

• Certara to Participate in the Barclays Global Healthcare Conference 2023

  2/27/2023

  Certara, Inc., a global leader in biosimulation, announced that Company management will participate in the Barclays Global Healthcare Conference.

• Certara to Report Fourth Quarter and Full Year 2022 Financial Results on March 1st, 2023

  2/1/2023

  Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it will release financial results for the fourth quarter and full year of 2022 after the market close on Wednesday, March 1st, 2023.

• Certara Acquires Vyasa, an Artificial Intelligence Company that Delivers Predictions to Accelerate Scientific InnovationCertara improves software capabilities by expanding into deep learning and data fabric

  1/4/2023

  Certara, Inc., announced it has acquired Vyasa Analytics, LLC. Vyasa provides scalable deep-learning software which allows life sciences organizations to perform predictions and answer complex questions across structured and unstructured bio-medical information.

• Certara Announces the Completion of Arsenal Capital Partners’ Investment and the Appointment of David Spaight to the Board of Directors

  12/8/2022

  Certara, Inc. announced that Arsenal Capital Partners, a private equity firm specializing in investing in and building transformational healthcare companies, closed its previously announced $449 million new investment in Certara.

• Certara Reports Third Quarter 2022 Financial Results

  11/7/2022

  Certara, Inc., a global leader in biosimulation, reported its financial results for the third quarter of fiscal year 2022 and reiterated its full year guidance.

• Arsenal Capital Partners Increases Investment in Global Biosimulation Leader Certara with $449M Stock Purchase

  11/7/2022

  Certara, Inc. announced that Arsenal Capital Partners, a private equity firm specializing in investing in and building transformational healthcare companies, has committed to make a new $449M investment in Certara.

• Certara to Participate in Upcoming November 2022 Investor Conferences

  11/2/2022

  Certara, Inc., a global leader in biosimulation, announced that Company management will participate in the following investor conferences.

• Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) Renews Licenses of Certara’s Software for Evaluating Regulatory Submissions

  10/19/2022

  Certara, Inc., (Nasdaq: CERT) a global leader in biosimulation, today announced that the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) has renewed its licenses of Certara’s Simcyp™ Simulator, Phoenix™ biosimulation software, and Pinnacle 21™ Enterprise software.